Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease

[1]  C. Tanner,et al.  Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study , 2023, The Lancet Neurology.

[2]  G. Kerchner,et al.  Aromatic L-Amino Acid Decarboxylase is a novel fluid biomarker of Parkinson's disease , 2022, medRxiv.

[3]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[4]  Sonja W. Scholz,et al.  Challenges in the diagnosis of Parkinson's disease , 2021, The Lancet Neurology.

[5]  P. Svenningsson,et al.  Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration , 2021, Movement disorders : official journal of the Movement Disorder Society.

[6]  P. Svenningsson,et al.  Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[7]  Weiguo Liu,et al.  Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease , 2020, Frontiers in Neurology.

[8]  C. Figueroa,et al.  Involvement of Kallikrein-Related Peptidases in Nervous System Disorders , 2020, Frontiers in Cellular Neuroscience.

[9]  Xuying Liu,et al.  IL-17D: A Less Studied Cytokine of IL-17 Family , 2020, International Archives of Allergy and Immunology.

[10]  L. Fugger,et al.  Inflammation-related plasma and CSF biomarkers for multiple sclerosis , 2020, Proceedings of the National Academy of Sciences.

[11]  G. Plazzi,et al.  Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies , 2020, Acta Neuropathologica.

[12]  H. Berendse,et al.  Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series , 2020, Acta Neuropathologica Communications.

[13]  S. Sardi,et al.  Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease , 2020, Scientific Reports.

[14]  H. Mochizuki,et al.  Parkinson’s disease and iron , 2020, Journal of Neural Transmission.

[15]  O. Hansson,et al.  Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease , 2019, Acta Neuropathologica Communications.

[16]  B. Bloem,et al.  Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms , 2019, BMC neurology.

[17]  P. Svenningsson,et al.  α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients , 2019, Proceedings of the National Academy of Sciences.

[18]  J. Rowe,et al.  Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  H. Shimada,et al.  Diagnostic impact of high serum midkine level in patients with gastric cancer , 2019, Annals of gastroenterological surgery.

[20]  M. Carl,et al.  An Eye on the Wnt Inhibitory Factor Wif1 , 2018, Front. Cell Dev. Biol..

[21]  S. Arnold,et al.  Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias , 2018, Proteomes.

[22]  B. Becher,et al.  IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression , 2017, Scientific Reports.

[23]  Xuan Jing,et al.  Diagnostic accuracy of ELISA for detecting serum Midkine in cancer patients , 2017, PloS one.

[24]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[25]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[26]  Michael D. Gregory,et al.  Common Variation in the DOPA Decarboxylase (DDC) Gene and Human Striatal DDC Activity In Vivo , 2016, Neuropsychopharmacology.

[27]  S. Ourselin,et al.  Neurofilament light chain: a biomarker for genetic frontotemporal dementia , 2016, Annals of clinical and translational neurology.

[28]  P. Steinacker,et al.  Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins , 2016, Movement disorders : official journal of the Movement Disorder Society.

[29]  M. Frasier,et al.  The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort , 2016, Movement disorders : official journal of the Movement Disorder Society.

[30]  J. Potempa,et al.  Kallikreins - The melting pot of activity and function. , 2016, Biochimie.

[31]  J. Clements,et al.  The kallikrein-related peptidase family: Dysregulation and functions during cancer progression. , 2016, Biochimie.

[32]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[33]  Jan Booij,et al.  The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review , 2015, EJNMMI Research.

[34]  Nick C Fox,et al.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  D. Jones.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases , 2014, British journal of pharmacology.

[36]  A. Mast,et al.  Biology of tissue factor pathway inhibitor. , 2014, Blood.

[37]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[38]  A. Lees,et al.  Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  M. Bertoldi.  Mammalian Dopa decarboxylase: structure, catalytic activity and inhibition. , 2014, Archives of biochemistry and biophysics.

[40]  A. Bonnet,et al.  Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. , 2014, Parkinsonism & related disorders.

[41]  M. Fisher.  Brain Regulation of Thrombosis and Hemostasis: From Theory to Practice , 2013, Stroke.

[42]  T. Arendt,et al.  The Role of Smad Proteins for Development, Differentiation and Dedifferentiation of Neurons , 2013 .

[43]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[44]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[45]  L. Lanfumey,et al.  Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson’s disease , 2011, Journal of Neural Transmission.

[46]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[47]  E. Masliah,et al.  Increased BMP6 Levels in the Brains of Alzheimer's Disease Patients and APP Transgenic Mice Are Accompanied by Impaired Neurogenesis , 2010, The Journal of Neuroscience.

[48]  Angelo Antonini,et al.  Levodopa in the treatment of Parkinson’s disease: an old drug still going strong , 2010, Clinical interventions in aging.

[49]  N. Mackman,et al.  Tissue factor: past, present, and future. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[50]  D. Matsuzawa,et al.  Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[51]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[52]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[53]  Yin Xia,et al.  Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. , 2007, The Journal of clinical investigation.

[54]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[55]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[56]  A. Rademaker,et al.  Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. , 2004, Clinical biochemistry.

[57]  P. Libby,et al.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.

[58]  T. Aikou,et al.  Serum midkine levels are increased in patients with various types of carcinomas , 2000, British Journal of Cancer.

[59]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[60]  R. Fitzpatrick,et al.  The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.

[61]  K. Unsicker,et al.  Bone Morphogenetic Proteins: Neurotrophic Roles for Midbrain Dopaminergic Neurons and Implications of Astroglial Cells , 1997, The European journal of neuroscience.

[62]  Daniel J Buysse,et al.  The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research , 1989, Psychiatry Research.

[63]  A. Zigmond,et al.  The Hospital Anxiety and Depression Scale , 1983, Acta psychiatrica Scandinavica.

[64]  D. Matsuzawa,et al.  Midkine in Psychiatric and Neurodegenerative Diseases , 2012 .

[65]  Xiao-Fan Wang,et al.  Signaling cross-talk between TGF-β/BMP and other pathways , 2009, Cell Research.